The 10th edition of BioAsia 2013, a platform for biotechnology and life sciences industry, will kick-start from January 28 here.
“We have finalised 20 regulators from across 15 countries for the BioAsia summit,” said PV Appaji, Director-General, Pharmaceuticals Export Promotion Council (Pharmexcil).
The market for biosimilars, he said, was expected to reach $10 billion by 2015, from $580 million in 2012. “As the biologics market is growing substantially, the biosimilars market too is gaining significant momentum with the industry looking to launch generic versions of the biotech drugs,” he told the media at the curtain-raiser of the three-day event.
Biopharmaceuticals with a total market value of over $78 billion is anticipated to lose it patent protection by 2015. Hence, the pharmaceutical industry has recognised this particular market opportunity and major investments were being made by key players, he said. “In India over 100 companies are actively involved in R&D and marketing of biosimilars including Dr Reddy’s, Intas and Reliance Lifesciences,” he said.